As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: November 30, 2011
by Medscape News:
The time has come for more rigorous studies that look into the potential of lipid-lowering statins in the prevention and/or treatment of Alzheimer’s disease (AD), authors of a new review of the literature conclude.
For a variety of reasons, studies to date have “precluded a clear answer to the overarching question of whether statins, such widely prescribed and generally safe drugs in our society, represent viable therapeutic or preventive agents for the most common cause of progressive cognitive failure in older humans,” they note.
The authors are Dennis J. Selkoe, MD, and Nina E. Shepardson, MS, both from the Center for Neurologic Diseases, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, and Ganesh M. Shankar, MD, PhD, who is also from the Center for Neurologic Diseases, as well as the Department of Neurological Surgery, Massachusetts General Hospital, Boston.
The review is published in the November issue of the Archives of Neurology.
Jury Still Out
A substantial amount of evidence supports the hypothesis that high cholesterol levels increase the risk of developing AD by promoting the formation of amyloid beta and its accumulation in the brain, the authors note. This has fueled numerous studies of whether statins and other lipid-lowering agents act as preventive or therapeutic agents in AD.
However, clinical studies of statins to date have shown “highly variable outcomes, making it difficult to draw firm conclusions,” the researchers point out.
Dr. Selkoe and colleagues believe several factors are behind the divergent outcomes seen in studies to date; chiefly, the different biochemical properties of the statins and other lipid-lowering agents used in the studies; differing blood–brain barrier permeabilities among statins; the drugs’ pleiotropic metabolic effects; the stage in AD at which statins were tested; and the inconsistent use of biomarker and cognitive endpoints.
The authors suggest that in the future, studies that investigate the potential link between statin use and AD risk or progression take into account the blood–brain permeabilities of statins when analyzing results.
John Ringman, MD, associate professor of neurology at the University of California, Los Angeles, School of Medicine, who was not involved in the review, agrees. “It is important the blood–brain barrier permeability be taken into consideration” in future studies, he told Medscape Medical News.
Dr. Selkoe and colleagues also recommend that future epidemiological studies and clinical trials uniformly apply an agreed-on set of biomarkers in serum and cerebrospinal fluid, particularly amyloid beta42, tau, and phospho-tau levels; that they employ brain imaging, including amyloid imaging by positron-emission tomography; and that they use cognitive measures such as the cognitive subscale of the AD Assessment Scale and, preferably, more sophisticated and specific tests of verbal and episodic memory.
Dr. Ringman said he “wouldn’t bother with more epidemiological studies. What we need now is randomized, blinded, placebo-controlled studies.”
It is also “most important,” say Dr. Selkoe and colleagues, to conduct statin treatment trials “solely in patients with mild AD, who have the best chance for disease modification.”
Dr. Ringman agrees. This patient population “is becoming the standard for testing interventions that are thought to have disease-modifying effects,” he said. Future studies “should be prospective studies that include participants with early- and presymptomatic-stage disease and have sensitive cognitive and biomarker endpoints,” he added.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.